Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Improved Expansion of Peripheral Blood and iPSC-Derived Natural Killer Cells for Clinical Applications

Jaya Lakshmi Thangaraj, Edith Lopez, Dan S Kaufman

Blood (2024) 144 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2024-205859

Published: 2024

Journal Articles

Human iPSC-Derived NK Cells with Knock-in of the BCL2 G101V Mutation Are Resistant to Venetoclax and Demonstrate Improved Anti-AML Activity In Vivo

Benjamin Goldenson, Davide Bernareggi, Jiyoung Yun, Samuel Shia, Dan S Kaufman

Blood (2023) 142 (Supplement 1): 464.

https://doi.org/10.1182/blood-2023-177527

Published: 2023

Journal Articles

Engineering Superaffinity Antibody Dependent Cellular Cytotoxcity Receptors into iPSC-Derived NK Cells As Next-Generation Immunotherapies for Cancer

Spencer Goodman, Kenyon Lyon, Katelin Hartwig, Suping Peng, Qin Li, David Murray, Davide Bernareggi, Caryn Gonsalves, Max Schabla, Guoxin Zhang, Terri Harder, Baohu Ji, Leah Mitchell, Dan S Kaufman, Robert Hollingsworth, Huang Zhu

Blood (2023) 142 (Supplement 1): 2060.

https://doi.org/10.1182/blood-2023-181261

Published: 2023

Journal Articles

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Jennifer N. Saultz, Daniel Bottomly, Faith Burns, Kaelan Byrd, Yoko Kosaka, Shannon K. McWeeney, Stephen E. Kurtz, Guang Fan, Andy Kaempf, Karen McGovern, Lei Wang, Marta Sanchez-Martin, Dan S Kaufman, Evan F. Lind, Jeffrey W. Tyner

Blood (2022) 140 (Supplement 1): 3071–3072.

https://doi.org/10.1182/blood-2022-163166

Published: 2022

Journal Articles

A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy

Davide Bernareggi, Caryn Gonsalves, Max Schabla, Alejandra Garate-Carrilo, Mohammad El-Kalay, Dan S Kaufman, Robert Hollingsworth, Huang Zhu

Blood (2022) 140 (Supplement 1): 1613–1614.

https://doi.org/10.1182/blood-2022-163871

Published: 2022

Journal Articles

Knock-in of the BCL2 G101V Mutation in Human iPSC-Derived NK Cells Generates Venetoclax Resistance and Improves Activity Against Venetoclax Resistant AML

Davide Bernareggi, Jiyoung Yun, Benjamin Goldenson, Dan S Kaufman

Blood (2022) 140 (Supplement 1): 7407–7408.

https://doi.org/10.1182/blood-2022-160203

Published: 2022

Journal Articles

Targeted Genomic Insertion of Cars in iPSC-Derived Macrophages Leads to Improved Expression and Anti-Tumor Activity

Yuelin Kong, Manuel Fierro, Somayeh Pouyanfard, Dan S Kaufman

Blood (2022) 140 (Supplement 1): 7390–7391.

https://doi.org/10.1182/blood-2022-159752

Published: 2022

Journal Articles

Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors

Lee Swanson, Kenyon Lyon, Wael Tadros, Mafalda Loreti, Tammy Babin, Benjamin Blair, Max Schabla, Paschalis Sideras, Dan S Kaufman, Robert Hollingsworth, Huang Zhu

Blood (2022) 140 (Supplement 1): 4540–4541.

https://doi.org/10.1182/blood-2022-163884

Published: 2022

Journal Articles

Development of Chimeric Antigen Receptor-Expressing iPSC-Derived Macrophages with Improved Anti-Tumor Activity

Somayeh Pouyanfard, Manuel Fierro, Dan S Kaufman

Blood (2021) 138 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2021-148687

Published: 2021

Journal Articles

iPSC-Derived Natural Killer Cells and Macrophages Synergistically Kill Acute Myeloid Leukemia Blasts

Benjamin Goldenson, Manuel Fierro, Somayeh Pouyanfard, Dan S Kaufman

Blood (2021) 138 (Supplement 1): 1692.

https://doi.org/10.1182/blood-2021-148618

Published: 2021

Journal Articles

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138527

Published: 2020

Journal Articles

ADAM17-Deficient Pluripotent Stem Cell-Derived Natural Killer Cells Possess Improved Antibody-Dependent Cellular Cytotoxicity and Antitumor Activity

Kenta Yamamoto, Robert Blum, Dan S Kaufman, MDPhD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-137766

Published: 2020

Journal Articles

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Huang Zhu, Robert H. Blum, Ryan Bjordahl, Svetlana Gaidarova, Paul Rogers, Tom Tong Lee, Ramzey Abujarour, Gregory B. Bonello, Jianming Wu, Pei-Fang Tsai, Jeffrey S. Miller, Bruce Walcheck, Bahram Valamehr, Dan S. Kaufman

Blood (2020) 135 (6): 399–410.

https://doi.org/10.1182/blood.2019000621

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

Huang Zhu, PhD, Robert Blum, Zhengming Wu, Zhipeng Meng, PhD, Kun-Liang Guan, PhD, Dan S Kaufman, MD PhD

Blood (2019) 134 (Supplement_1): 619.

https://doi.org/10.1182/blood-2019-124446

Published: 2019

Journal Articles

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Jeffrey S. Miller, MD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Ge Moyar, Bruce R. Blazar, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD, Frank Cichocki, PhD

Blood (2019) 134 (Supplement_1): 1933.

https://doi.org/10.1182/blood-2019-124961

Published: 2019

Journal Articles

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Karrune Woan, MD PhD, Frank Cichocki, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Jason Dinella, PhD, Lauren Fong, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 133.

https://doi.org/10.1182/blood-2019-131138

Published: 2019

Journal Articles

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Jode P Goodridge, PhD, Sajid Mahmood, PhD, Huang Zhu, PhD, Svetlana Gaidarova, MS, Robert Blum, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 301.

https://doi.org/10.1182/blood-2019-129319

Published: 2019

Journal Articles

KIR Expression on in Vitro -Derived Natural Killer Cells Does Not Regulate Killing of Allogeneic Targets

Yunzu Michele Wang, MD, Huang Zhu, PhD, Alessa Ruiz-Cisneros, Naveen Heragu, BS, Eivind Heggernes Ask, Hanna Julie Hoel, Karl-Johan Malmberg, MD PhD, Dan S Kaufman, MD PhD

Blood (2018) 132 (Supplement 1): 3705.

https://doi.org/10.1182/blood-2018-99-117151

Published: 2018

Journal Articles

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Dan S Kaufman, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 730.

https://doi.org/10.1182/blood-2018-99-114893

Published: 2018

Journal Articles

Human Pluripotent Stem Cell-Derived Blood Cells for Therapies

Dan S Kaufman, MD PhD

Blood (2018) 132 (Supplement 1): SCI-14.

https://doi.org/10.1182/blood-2018-99-109424

Published: 2018

NARROW

Improved Expansion of Peripheral Blood and iPSC-Derived Natural Killer Cells for Clinical Applications

Human iPSC-Derived NK Cells with Knock-in of the BCL2 G101V Mutation Are Resistant to Venetoclax and Demonstrate Improved Anti-AML Activity In Vivo

Engineering Superaffinity Antibody Dependent Cellular Cytotoxcity Receptors into iPSC-Derived NK Cells As Next-Generation Immunotherapies for Cancer

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy

Knock-in of the BCL2 G101V Mutation in Human iPSC-Derived NK Cells Generates Venetoclax Resistance and Improves Activity Against Venetoclax Resistant AML

Targeted Genomic Insertion of Cars in iPSC-Derived Macrophages Leads to Improved Expression and Anti-Tumor Activity

Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors

Development of Chimeric Antigen Receptor-Expressing iPSC-Derived Macrophages with Improved Anti-Tumor Activity

iPSC-Derived Natural Killer Cells and Macrophages Synergistically Kill Acute Myeloid Leukemia Blasts

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

ADAM17-Deficient Pluripotent Stem Cell-Derived Natural Killer Cells Possess Improved Antibody-Dependent Cellular Cytotoxicity and Antitumor Activity

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

KIR Expression on in Vitro -Derived Natural Killer Cells Does Not Regulate Killing of Allogeneic Targets

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Human Pluripotent Stem Cell-Derived Blood Cells for Therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only